Physician profile
Ashley Ann Ader
NPI 1821666264
$679.26
in general payments reported to CMS, 2019-2025
15 companies · $631 in 2025
The $631 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $48.39 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90.20 | 2025 | Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $89.25 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Beone Medicines USA, INC. | $79.05 | 2025 | Brukinsa, Tevimbra |
| Novartis Pharmaceuticals Corporation | $51.04 | 2025 | |
| Merz North America, INC. | $48.39 | 2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $44.16 | 2025 | |
| Geron Corporation | $43.97 | 2025 | Rytelo |
| Janssen Biotech, INC. | $43.18 | 2025 | Erleada, Darzalex, Tecvayli |
| Incyte Corporation | $42.56 | 2025 | Jakafi, Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $32.84 | 2025 | |
| Caris Mpi, INC. | $32.56 | 2025 | Mi Cancer Seek |
| Iovance Biotherapeutics, INC. | $26.55 | 2025 | Amtagvi |
| Daiichi Sankyo INC. | $22.57 | 2025 | Datroway |
| Sumitomo Pharma America, INC. | $16.61 | 2025 | Orgovyx |
| Coherus Oncology, INC. | $16.33 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.